Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biovail v. Andrx

Executive Summary

Andrx may "sue the FDA directly under the [administrative procedure act] to compel the FDA to approve" its diltiazem ANDA (Taztia XT), the D.C. federal appeals court says in reversing a Miami federal district court decision lifting the 30-month stay on approval of generic versions of Biovail's Tiazac (1"The Pink Sheet" Sept. 24, 2001, p. 12). The patent infringement trial is scheduled for June 3...

You may also be interested in...

Andrx Generic Tiazac Open For Approval; Court Lifts 30-Month Stay

The stay of approval on Andrx' generic version of Biovail/Forest's Tiazac (diltiazem) will be lifted Sept. 27, Miami federal court Judge William Dimitrouleas ruled Sept. 19.

Could SillaJen Get Back On Track Via M2N Acquisition?

SillaJen selects another Korean firm as its new owner as trading in its stock continues to be suspended following the probe into its former CEO. But it remains to be seen whether the acquisition can catalyze a business breakthrough and speed up clinical development for the oncolytic immunotherapeutic firm.

QUOTED. 15 April 2021. Philip Remedios.

As wearable medical devices become increasingly common for more complex applications, developers are facing questions about the industry’s direction and how they will protect consumers. See what Philip Remedios, director of design and development at Black Hagen Design said about it here. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts